OakChart

Rallybio Corp

RLYBHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

15.80+0.04 (0.25%)
2026-11-12 00:12 CET
Market cap
84.85 USD m
Revenue, TTM
0.43 USD m
Net income, TTM
26.81 USD m
Free cash flow, TTM
30.99 USD m
EPS diluted, TTM
4.49
P/E
3.52
Compare

Price

RLYB against its 20, 50 and 200-day averages
2050200
10.0015.00226K452KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RLYBclose 15.8020-day 16.0450-day 16.57200-day 13.3515.8052w high

10.1% under the 52-week high of 17.57 on 1 Jun 2026. 52-week low 3.67 on 17 Feb 2026. Last 15 sessions, 9.8% high to low

Volume 2.44× normal · the line is the 50-bar volume average

Profile

RLYB
52-week range, 87% of the way up
3.6717.57

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Employees14
IPOJul 29, 2021
Beta-0.77
ATR, 14d0.52
Rel volume2.44
Short float0.94%
Insider own23.23%
Inst own59.23%

Snapshot

6 groups

Valuation

Index-
Market Cap85.07M
Enterprise Value-5.62M
Income26.81M
Sales0.43M
Book/sh17.31
Cash/sh16.84
Dividend Est.-
Dividend TTM-
Dividend Ex-DateNov 06, 2026
Dividend Gr. 3/5Y- -
Payout-
Employees14
IPOJul 29, 2021

Ratios

P/E3.52
Forward P/E-
PEG-
P/S197.83
P/B0.91
P/C0.94
P/FCF2.74
EV/EBITDA-
EV/Sales-13.08
Quick Ratio28.87
Current Ratio28.87
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)4.49
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y54.34% 24.69%
Sales past 3/5Y- -
EPS Y/Y TTM281.10%
Sales Y/Y TTM-35.61%
EPS Q/Q-116.77%
Sales Q/Q-100.00%
Earnings-
EPS/Sales Surpr.268.75% 217.84%

Ownership

Insider Own23.23%
Insider Trans13.21%
Inst Own59.23%
Inst Trans-29.08%
ROA32.85%
ROE34.52%
ROIC29.05%
Gross Margin98.16%
Oper. Margin-4659.22%
Profit Margin6177.42%
SMA20-1.48%
SMA50-4.64%
SMA20018.36%
Trades-

Technical

Shs Outstand5.33M
Shs Float4.13M
Short Float0.94%
Short Ratio2.13
Short Interest0.04M
52W High17.57 -10.09%
52W Low3.67 330.51%
Volatility2.99% 3.19%
ATR (14)0.52
RSI (14)42.00
Beta-0.77
Rel Volume2.44
Avg Volume18.33K
Volume44,688

Performance

Perf Week-0.63%
Perf Month-5.50%
Perf Quarter-6.84%
Perf Half Y10.10%
Perf YTD187.86%
Perf Year180.14%
Perf 3Y-31.18%
Perf 5Y-88.71%
Perf 10Y-
Recom2.50
Target Price8.00
Prev Close15.76
Price15.80
Change %0.25%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Apr 09, 2025DowngradeHH.C. WainwrightBuy → Neutral
May 15, 2024DowngradeJJP MorganOverweight → Neutral
Feb 07, 2024DowngradeJJefferiesBuy → Hold$7 → $1.50-90.5%
Apr 17, 2023InitiatedHH.C. WainwrightBuy$18+13.9%
Apr 10, 2023InitiatedWWedbushOutperform$17+7.6%
Dec 09, 2022InitiatedJJP MorganOverweight$21+32.9%
Feb 22, 2022InitiatedJJMP SecuritiesMkt Outperform$32+102.5%
Aug 23, 2021InitiatedJJefferiesBuy$20+26.6%
Aug 23, 2021InitiatedEEvercore ISIOutperform$40+153.2%
Aug 23, 2021InitiatedCCowenOutperform

Peers

Mkt cap
TickerCompanyMkt cap
OLMAOlema Pharmaceuticals Inc703.48M
CELCCelcuity Inc3.16B
ARVNArvinas Inc452.51M
RLAYRelay Therapeutics Inc4.36B
STROSutro Biopharma Inc170.12M
INCYIncyte Corp24.92B
ACRVAcrivon Therapeutics Inc67.28M
BDTXBlack Diamond Therapeutics Inc92.50M
ZYMEZymeworks BC Inc2.02B
PFEPfizer Inc167.86B

Insider trading

latest 14 of 27
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
MACKAY MARTINDirectorNov 04 '26Option Exercise5.3333,224177,036125,032Nov 05 05:04 PM
HUNT RONALDDirectorNov 04 '26Option Exercise4.4514,30563,65729,125Nov 05 05:03 PM
Lieber Jonathan IChief Financial OfficerNov 02 '26Option Exercise14.887,124106,00544,139Nov 03 05:51 PM
Lieber Jonathan IChief Financial OfficerOct 29 '26Option Exercise9.3121,464199,80137,015Nov 02 05:27 PM
HUNT RONALDDirectorOct 29 '26Option Exercise7.4114,820109,87514,820Nov 02 05:17 PM
Nash Christine ADirectorOct 28 '26Option Exercise2.383,5628,4783,562Oct 30 06:06 PM
Uden StephenChief Executive OfficerOct 27 '26Option Exercise6.0833,244202,124148,864Oct 29 05:20 PM
Lieber Jonathan IChief Financial OfficerOct 27 '26Sale16.045999,60815,551Oct 28 05:03 PM
Chung WendyDirectorOct 26 '26Option Exercise15.282,06231,5075,624Oct 28 05:03 PM
Soteropoulos PaulaDirectorOct 16 '26Option Exercise2.383,5628,4786,544Oct 20 05:32 PM
Boudreau Helen MDirectorOct 16 '26Option Exercise15.282,06231,5078,604Oct 20 05:29 PM
Hopfner Robert LorneDirectorOct 12 '26Option Exercise7.4114,820109,87514,820Oct 14 04:34 PM
Lieber Jonathan IChief Financial OfficerOct 09 '26Option Exercise6.083,91023,77313,650Oct 13 04:50 PM
Uden StephenChief Executive OfficerOct 06 '26Option Exercise6.0822,456136,532115,620Oct 08 05:04 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 665.71M
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q42026-03-17-1.280-1.240-1.1080.000.102
2025Q32025-11-062.880-1.7072.8800.210.073
2025Q22025-08-07-1.760-1.960-1.7310.210.002
2025Q12025-05-08-1.680-2.080-1.6870.210.003
2024Q42025-03-13-2.000-2.300-1.9780.040.154
2024Q32024-11-07-2.080-2.816-2.0570.300.085
2024Q22024-08-08-2.960-2.994-2.9430.300.005
2024Q12024-05-09-3.760-3.787-3.7340.000.005
2023Q42024-03-12-4.000-3.589-3.9850.000.006
2023Q32023-11-09-3.600-4.070-3.6270.000.007
2023Q22023-08-08-3.680-3.832-3.6920.000.007
2023Q12023-05-09-3.440-3.883-3.4420.000.007
2022Q42023-03-06-3.680-4.768-3.6500.000.005
2022Q32022-11-07-4.800-4.340-4.7750.000.004
2022Q22022-08-08-4.560-4.760-4.5990.000.004
2022Q12022-05-10-3.840-3.620-3.8260.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-14.720-28.320-11.7060.000.00
2022FY-16.720-18.040-16.7570.000.00
2023FY-14.720-14.341-14.7480.000.00
2024FY-10.640-11.360-10.6400.640.67
2025FY-1.840-1.800-1.5950.600.70
2026FY--5.520--0.00
2027FY--11.520---
2028FY--3.120---
2029FY-3.920--89.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q1S2026-03-171000.000.000.00
2026Q1S2025-11-061000.000.000.00
2026Q1S2025-08-071000.000.000.00
2026Q1S2025-05-251000.000.000.00
2026Q1S2025-05-241000.000.000.00
2026Q1S2025-05-231000.000.000.00
2026Q1S2025-05-221000.000.000.00
2026Q1S2025-05-211000.000.000.00
2026Q1S2025-05-201000.000.000.00
2026Q1S2025-05-191000.000.000.00
2026Q1S2025-05-181000.000.000.00
2026Q1S2025-05-171000.000.000.00
2026Q1S2025-05-161000.000.000.00
2026Q1S2025-05-151000.000.000.00

Estimate history

EPS, annual-4.373-6.585-11.706-16.757-14.748-10.614-1.5954.4916
Period2019202020212022202320242025TTM
EPS, quarterly-2.057-1.978-1.687-1.7312.844-1.108-1.4557.531-0.477
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000.6360.8580.43
Period2019202020212022202320242025TTM
Sales, quarterly0.2990.0380.2120.2120.2120.2220.21200
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual4.0164.0164.0164.734.7295.1895.2835.333
Period2019202020212022202320242025MRQ
Shares, quarterly5.1865.1895.2025.2135.2425.2835.295.3075.333
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.430.860.640.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.090.130.150.170.110.060.03
Gross Profit0.430.770.51-0.15-0.17-0.11-0.06-0.03
Selling, General and Administrative Excl. Other20.6528.8361.0078.7867.7245.5425.2417.62
Research and Development5.0616.3041.3853.3940.5226.8017.5711.34
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-20.22-28.06-60.50-78.93-67.88-45.65-25.30-17.64
Interest Expense0.000.000.000.000.000.010.050.04
Unusual Expense-46.005.000.000.000.000.000.000.14
Net Income Before Taxes28.21-8.10-55.54-72.52-65.58-45.51-24.94-17.46
Income Taxes1.400.000.000.000.000.00-0.010.00
Consolidated Net Income26.81-8.98-57.77-74.56-66.65-47.01-26.45-17.56
Net Income From Continuing Operations26.81-8.98-57.77-74.56-66.65-47.01-26.45-17.56
Net Income26.81-8.98-57.77-74.56-66.65-47.01-26.45-17.56
EPS (Recurring)-0.94-0.97-10.61-14.75-16.76-11.71-6.59-4.35
EPS (Basic, Before Extraordinaries)4.62-1.59-10.61-14.75-16.76-11.71-6.58-4.37
EPS (Diluted)4.49-1.59-10.61-14.75-16.76-11.71-6.58-4.37
EBITDA-20.21-27.97-60.37-78.78-67.72-45.54-25.24-17.62
Non-Operating Income (Expense)2.4424.964.966.412.310.150.410.36
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.045.317.9910.929.503.650.510.51
Price To Earnings Ratio3.513.51------
Price To Sales Ratio226.4936.0165.73-----
Gross Margin98.1689.2879.40-----
Operating Margin-4,659.22-3,270.86-9,511.95-----
Net Margin6,177.42-1,046.39-9,084.12-----
Shares Outstanding5.335.285.194.734.734.024.024.02
Market Capitalization84.8584.8539.8590.34210.84306.52311.66-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.210.220.210.210.210.04
Cost of Goods Sold Incl. D&A0.000.000.000.000.040.030.030.03
Gross Profit0.00-0.000.210.220.180.190.180.01
Selling, General and Administrative Excl. Other3.425.654.946.635.408.549.8511.62
Research and Development0.580.760.073.652.914.855.707.36
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.42-5.65-4.73-6.41-5.22-8.36-9.67-11.61
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.00-50.004.000.001.701.700.000.00
Net Income Before Taxes-2.6544.99-8.28-5.8516.02-9.42-8.85-10.61
Income Taxes0.081.320.000.000.000.000.000.00
Consolidated Net Income-2.7343.66-8.28-5.8516.02-9.70-9.44-11.04
Net Income From Continuing Operations-2.7343.66-8.28-5.8516.02-9.70-9.44-11.04
Net Income-2.7343.66-8.28-5.8516.02-9.70-9.44-11.04
EPS (Recurring)-0.481.49-0.96-1.113.05-1.52-1.69-1.98
EPS (Basic, Before Extraordinaries)-0.487.66-1.46-1.112.84-1.73-1.69-1.98
EPS (Diluted)-0.487.53-1.46-1.112.84-1.73-1.69-1.98
EBITDA-3.42-5.65-4.73-6.41-5.19-8.33-9.64-11.58
Non-Operating Income (Expense)0.780.640.460.5622.940.640.820.99
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.320.330.610.771.051.611.881.96
Price To Earnings Ratio3.51-------
Price To Sales Ratio226.49143.6059.4733.8033.3619.9234.5667.41
Gross Margin--98.5898.6583.4987.7486.7921.05
Operating Margin---2,232.55-2,888.29-2,464.62-3,941.98-4,561.32-30,547.37
Net Margin---3,904.72-2,636.047,554.72-4,576.89-4,452.36-29,063.16
Shares Outstanding5.335.315.295.285.245.215.205.19
Market Capitalization84.8584.8047.4529.0020.9314.1027.2439.85

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments54.7465.51109.93168.99175.33140.2319.46
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets6.522.334.8610.505.541.031.46
Total Current Assets61.2567.84114.79179.50180.87141.2620.92
Net Property, Plant & Equipment0.200.270.590.910.510.290.20
Total Investments and Advances0.000.000.240.030.810.310.49
Intangible Assets-0.000.000.000.000.000.00
Other Assets0.810.000.000.000.000.000.00
Total Assets62.2668.11115.62180.44182.19141.8621.61
Short Term Debt Incl. Current Port. of LT Debt0.090.150.220.180.000.000.00
Accounts Payable0.130.280.981.110.601.580.86
Other Current Liabilities4.005.818.079.455.954.262.95
Total Current Liabilities4.226.249.2610.746.555.843.81
Long Term Debt0.080.000.170.370.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.210.000.000.030.010.94
Total Liabilities4.306.459.4411.126.585.864.75
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00182.0337.14
Common Equity57.9661.65106.18169.32175.60-46.02-20.28
Total Shareholders Equity57.9661.65106.18169.32175.60136.0016.86
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity57.9661.65106.18169.32175.60136.0016.86
Total Liabilities & Stockholders Equity62.2668.11115.62180.44182.19141.8621.61
Book Value Per Share10.9711.8822.4635.8043.72-11.46-5.05
Tangible Book Value Per Share10.9711.8822.4635.8043.72-11.46-5.05
Full-Time Employees1425434135--
Price to Book Ratio0.910.650.731.601.751.67-
Return on Assets-13.77-62.89-50.37-36.76-29.02-32.36-
Return on Equity-15.01-68.85-54.13-38.65-30.17-34.60-
Return on Invested Capital-15.47-93.71-70.11-39.28-26.77-19.45-104.17
Quick Ratio14.5010.8712.3916.7127.6124.185.50
Current Ratio14.5010.8712.3916.7127.6124.185.50

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income26.81-8.98-57.77-74.56-66.65-47.01-26.45-17.56
Depreciation0.010.090.130.150.170.110.060.03
Other Funds (Non Cash)2.08-16.738.629.8710.145.152.230.44
Funds from Operations28.90-25.62-49.02-64.54-56.35-41.75-24.16-17.10
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital2.09-4.19-0.264.28-0.94-3.782.122.07
Cash from Operating Activities30.99-29.81-49.28-60.27-57.28-45.53-22.04-15.03
Capital Expenditures0.000.000.00-0.01-0.05-0.33-0.14-0.19
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments27.3227.2733.4927.67-112.12-2.00-1.940.00
Purchase of Investments-7.08-19.20-50.93-110.66-201.62-2.00-1.940.00
Sale Or Maturity of Investments34.4046.4784.42138.3389.500.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.0020.000.000.000.000.000.000.00
Cash from Investing Activities27.3247.2733.4927.66-112.17-2.33-2.07-0.19
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.260.025.200.1451.0882.97144.8931.57
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.260.025.200.1451.0882.97144.8931.57
Proceedsfrom Stock Options0.000.00-0.27-0.1450.8482.97144.8931.57
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities0.260.025.200.1451.0882.97144.8931.57
Net Change in Cash58.5717.47-10.59-32.46-118.3835.10120.7816.35
Free Cash Flow30.99-29.81-49.28-60.28-57.34-45.87-22.18-15.21
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Price to Free Cash Flow3.17-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments90.6992.8546.8054.7459.3245.75
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets4.084.406.706.527.314.52
Total Current Assets94.7797.2553.4961.2566.6350.27
Net Property, Plant & Equipment0.000.000.170.200.220.11
Total Investments and Advances0.000.000.000.000.000.63
Intangible Assets-----0.00
Other Assets0.810.810.810.810.810.00
Total Assets95.5898.0654.4762.2667.6651.00
Short Term Debt Incl. Current Port. of LT Debt0.000.000.100.090.090.06
Accounts Payable0.010.830.940.130.270.12
Income Tax Payable1.351.27----
Other Current Liabilities1.931.473.104.004.164.86
Total Current Liabilities3.283.574.144.224.525.04
Long Term Debt0.000.000.060.080.110.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.283.574.204.304.635.04
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity92.3094.5050.2857.9663.0345.96
Total Shareholders Equity92.3094.5050.2857.9663.0345.96
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity92.3094.5050.2857.9663.0345.96
Total Liabilities & Stockholders Equity95.5898.0654.4762.2667.6651.00
Book Value Per Share17.3117.819.5010.9712.028.82
Tangible Book Value Per Share17.3117.819.5010.9712.028.82
Full-Time Employees---14--
Price to Book Ratio0.911.680.820.500.330.31
Return on Assets32.8561.12-13.90-13.77-19.32-58.08
Return on Equity34.5264.86-14.98-15.01-21.17-66.12
Return on Invested Capital-2.9546.21-16.45-10.0825.37-21.11
Quick Ratio28.8727.2612.9214.5014.749.98
Current Ratio28.8727.2612.9214.5014.749.98

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-2.7343.66-8.28-5.8516.02-9.70
Depreciation0.000.000.000.000.040.03
Other Funds (Non Cash)0.410.440.560.68-21.421.75
Funds from Operations-2.3244.10-7.71-5.17-5.37-7.93
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.041.81-0.270.49-1.19-0.45
Cash from Operating Activities-2.2845.92-7.98-4.68-6.55-8.38
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.005.5017.903.929.233.04
Purchase of Investments0.000.000.00-7.08-0.74-4.46
Sale Or Maturity of Investments0.005.5017.9011.009.967.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.0020.000.00
Cash from Investing Activities0.005.5017.903.9229.233.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.120.130.000.010.000.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.120.130.000.010.000.01
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.120.130.000.010.000.01
Net Change in Cash-2.1651.559.93-0.7522.68-5.33
Free Cash Flow-2.2845.92-7.98-4.68-6.55-8.38
Price to Free Cash Flow3.173.47----

Revenue breakdown

Pharmaceutical Preparations2024: 636.00K 2025: 858.00K
United States2024: 636.00K 2025: 858.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.94%0.0M4.1M16.33K
2026-10-151.00%0.0M4.1M16.14K
2026-09-301.20%0.0M4.1M23.08K
2026-09-151.34%0.1M4.1M29.25K
2026-08-311.33%0.1M4.1M43.20K
2026-08-141.32%0.1M4.1M50.09K
2026-07-311.60%0.1M4.0M238.65K
2026-07-154.28%0.2M4.0M246.26K
2026-06-3010.51%0.4M3.9M247.98K
2026-06-1510.93%0.4M3.9M255.00K
2026-05-2916.91%0.6M3.5M327.54K
2026-05-1516.68%0.6M3.5M335.55K
2026-04-3045.46%1.6M3.5M148.15K
2026-04-1544.35%1.4M3.2M144.11K
2026-03-3140.92%1.1M2.7M135.21K
2026-03-1329.44%0.8M2.7M118.85K
2026-02-271.64%0.0M2.7M33.84K
2026-02-131.44%0.0M2.7M22.44K
2026-01-300.66%0.0M2.7M23.54K
2026-01-150.54%0.0M2.7M25.53K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-11-108-KCurrent report2026-11-08SEC
2026-11-06425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-024Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-11-024Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-294Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-2710-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-26425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-268-KCurrent report2026-10-25SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-15EFFECTEffectiveness filing by commission orderSEC
2026-10-15424B3SEC
2026-10-14S-4/ASEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-05S-4/ASEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-16S-4/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10009.61K1
2026-090000
2026-080000
2026-070000
2026-060000
2026-054.23M800
2026-040000
2026-030000
2026-02003.99K1
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ADAR1 Capital Management, LLC17.48%
FMR LLC14.97%
VIKING GLOBAL INVESTORS LP9.89%
TPG GP A, LLC7.14%
Nantahala Capital Management, LLC7.11%
Pivotal bioVenture Partners Investment Advisor LLC5.67%
RENAISSANCE TECHNOLOGIES LLC3.77%
VANGUARD CAPITAL MANAGEMENT LLC3.25%
Almitas Capital LLC2.28%
Rangeley Capital, LLC1.98%

Funds

Fund% owned
Fidelity Small Cap Growth Fund190.11%
Fidelity Small Cap Growth K6 Fund97.41%
Select Biotechnology Portfolio71.87%
Fidelity Advisor Biotechnology Fund54.32%
Select Health Care Portfolio40.98%
Fidelity Advisor Health Care Fund20.66%
VIP Health Care Portfolio7.35%
Fidelity Growth Company Fund3.91%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.54%
Fidelity Growth Company K6 Fund1.07%

OakChart. RLYB. Cached 15 minutes.